Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized phase II-III study of chemoradiation with fluorouracil and cisplatin versus chemotherapy (gemcitabine/oxaliplatin) in non resectable but non metastatic cancer of the biliary tract

X
Trial Profile

Randomized phase II-III study of chemoradiation with fluorouracil and cisplatin versus chemotherapy (gemcitabine/oxaliplatin) in non resectable but non metastatic cancer of the biliary tract

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin; Fluorouracil; Gemcitabine; Oxaliplatin
  • Indications Biliary cancer; Biliary tract disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 May 2016 Biomarkers information updated
    • 02 Oct 2012 Results presented at the 37th Congress of the European Society for Medical Oncology.
    • 02 Oct 2012 Status changed from recruiting to discontinued based on results presented at the 37th Congress of the European Society for Medical Oncology. The study was closed before completion of the planned number of patients due to slow accrual.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top